Ustekinumab Market 2022

Industry Size, Emerging Trends, Regions, Growth Insights, Opportunities, and Forecast By 2033

Ustekinumab Market by Indication (Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, and Ulcerative Colitis), by Dosage Form (Capsule, Tablets), by Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies), and by Region – Global Share and Forecast to 2033

Region: Global | Format: Word, PPT, Excel | Report Status: Ongoing

According to the Market Statsville Group (MSG), the global ustekinumab market size is expected to grow at a CAGR of 8.1% from 2023 to 2033.

The global increase in the prevalence of psoriasis patients is the primary reason driving the market's growth rate. Moreover, growing healthcare spending is a major factor impacting the pace of growth of the ustekinumab market. Additionally, the growing elderly population and an increase in the number of clinical trial studies will drive the ustekinumab market. Additional factors such as increased government initiatives and more awareness will favourably influence the market growth rate. However, the high cost of the product will slow the market's growth pace. Side effects such as nausea, vomiting, dizziness, seizures, visual changes, disorientation, itching, hives, and trouble breathing, among others, may also impede the expansion of the ustekinumab market. Furthermore, the increase in R&D efforts and the emergence of new markets would give promising prospects for the ustekinumab market during the projection period.

Definition of the Global Ustekinumab Market

Janssen Pharmaceuticals developed stekinumab (Stelara), a monoclonal antibody medication that targets both IL-12 and IL-23, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Ustekinumab is approved for the treatment of Crohn's disease and ulcerative colitis in the United States, Israel, Australia, and the European Union (EU) in patients who have not responded to more conventional therapy. It was proven to be unsuccessful in the treatment of multiple sclerosis. Ustekinumab is used to treat psoriasis. It is approved for the treatment of adolescents (12 years and older) and adults with moderate to severe plaque psoriasis (Ps) who are not candidates for phototherapy or systemic therapy, as well as people with active psoriatic arthritis (PsA), either alone or in combination with methotrexate. It is also used to treat Crohn's disease and ulcerative colitis, which is moderate to extremely active.

COVID-19 Impact on the Global Ustekinumab Market

COVID-19 is an infectious illness that first appeared in late December in the Hubei province of Wuhan, China. The extremely infectious condition is caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It spreads from person to person. After the disease's breakout in December 2019, it has expanded to over 213 nations worldwide, prompting the World Health Organization to declare it a public health emergency on March 11, 2020. Pharmaceutical and biotech businesses and governments worldwide are attempting to handle the COVID-19 epidemic, from vaccine research to pharmaceutical supply chain issues planning. About 115 vaccine candidates and 155 compounds are in the R&D pipeline. Also, routinely used medications like hydroxychloroquine have seen a huge increase in demand for COVID-19 control. Because of the enormous demand for these treatments, makers of COVID-19 management pharmaceuticals have a lot of chances since many wealthy nations are running out of them. As a result of the demand for COVID-19 vaccination and treatment medications, the pharmaceutical and biotechnology sectors are predicted to increase significantly in the future. This, in turn, is expected to impact the ustekinumab market significantly.

Global Ustekinumab Market Dynamics

Drivers: Rise in the prevalence of psoriasis patients

Psoriasis is treated with Ustekinumab. When it comes to the skin, this includes psoriatic arthritis. Ustekinumab is approved for the treatment of adults and adolescents (12 years and older) with moderate to severe plaque psoriasis (Ps) who are not candidates for phototherapy or systemic therapy, as well as people with active psoriatic arthritis (PsA), either alone or in combination with methotrexate. Skin-related diseases are spreading all around the world due to unhealthy diets and poor lifestyles. Ustekinumab also treats Crohn's disease and ulcerative colitis, which is moderate to extremely active in various regions. Canada, the European Union, and the United States have approved using Ustekinumab. Ustekinumab is authorized to treat moderate to severe plaque psoriasis. Ustekinumab has been authorized by the US Food and Drug Administration (FDA) to treat psoriatic arthritis. This increase in the prevalence of using this drug for the treatment of skin-related diseases is boosting the market growth over the forecasting period.

Restraints: High Costs associated with Ustekinumab and high side effects

Stelara (ustekinumab) is an interleukin inhibitors medicine that is often used to treat Crohn's disease, plaque psoriasis, psoriasis, and other conditions. Stelara subcutaneous solution (45 mg/0.5 mL) costs around $13,971 for a supply of 0.5 milliliters. Moreover, this drug has many adverse effects, such as upper respiratory infection, headache, and tiredness.

Medication based on ustekinumab and their version of ustekinumab is linked to a variety of significant side effects. They include a higher chance of infection, such as TB, as well as a higher risk of some forms of cancer. The brain swelling of posterior reversible encephalopathy syndrome is a danger with several immunosuppressant medicines, such as ciclosporin. A significant allergic response is also listed as a possible adverse effect by the pharmaceutical firm. However, the cost associated with this drug and high side effects has hindered the market growth over the forecast period in all over the world.

Opportunities: Rise in the R&D of ustekinumab in emerging new markets

Expanding into emerging markets is a significant opportunity for the Ustekinumab market. Healthcare organizations in emerging markets are increasingly recognizing the benefits of Ustekinumab and are adopting it in new technology to improve its effectiveness in Ustekinumab. This growing demand for Ustekinumab for skin-related diseases in emerging markets creates new opportunities for market growth and expansion. Furthermore, the increase in R&D efforts and the emergence of new markets would give promising prospects for the ustekinumab market during the projection period. Furthermore, continuing economic development and improved healthcare infrastructure will be important market drivers, creating new potential for the industry's growth rate.

Scope of the Global Ustekinumab Market

The study categorizes the ustekinumab market based on indication, dosage form, and distribution channel area at the regional and global levels.

By Indication Outlook (Sales, USD Million, 2019-2033)

  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Crohn's Disease
  • Ulcerative Colitis

By Dosage Form Outlook (Sales, USD Million, 2019-2033)

  • Capsule
  • Tablets

By Distribution Channel Outlook (Sales, USD Million, 2019-2033)

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Online Pharmacies

By Region Outlook (Sales, USD Million, 2019-2033)

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Italy
    • France
    • UK
    • Spain
    • Poland
    • Russia
    • The Netherlands
    • Norway
    • Czech Republic
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Malaysia
    • Thailand
    • Singapore
    • Australia & New Zealand
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Rest of South America
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Northern Africa
    • Rest of MEA

Hospitals segment accounts for the largest market share by distribution channel

Based on the distribution channel, the market is divided into hospitals, clinics, retail pharmacies and online pharmacies. The hospital segment is expected to dominate the market share in 2022 in the global ustekinumab market. Ustekinumab is a medicine that is used to control and treat inflammatory disorders such as psoriasis, psoriatic arthritis, and inflammatory bowel disease. Ustekinumab is used in many hospitals to treat skin-related and other diseases. Due to these reasons, this segment has accounted for the largest market share over the forecast period.

North America is expected to witness the largest market share by Region

Based on the regions, the global ustekinumab market has been segmented across Europe, North America, the Middle East & Africa, Asia-Pacific, and South America. North America is projected to account for the highest market share in 2022. In North America, the demand for ustekinumab is growing as the government implements healthcare reform initiatives aimed at improving the efficiency and quality of healthcare services. The spread of skin-related diseases in this market has driven the market growth over the forecasting period.

Competitive Landscape: Global Ustekinumab Market

The ustekinumab market is a significant competitor, and extremely cutthroat in the sector are using strategies including product launches, partnerships, acquisitions, agreements, and growth to enhance their market positions. Most sector businesses focus on increasing their operations worldwide and cultivating long-lasting partnerships.

Major key players in the global ustekinumab market are:

  • Meiji
  • Johnson and Johnson
  • Alvotech
  • Fuji Pharma
  • Mitsubishi Tanabe
  • Stada
  • EPIRUS BioPharma
  • Formycon
  • NeuClone
  • Outlook Therapeutics
  • Company 11
  • Company 12
  • Company 13
  • Company 14
  • Company 15

Frequently Asked Questions

  • Key Issues Addressed
  • What is the market size and growth rate for different segmentations at a global, regional, & country level?
  • What is the customer buying behavior, key takeaways, and Porter's 5 forces of the market?
  • What are the key opportunities and trends for manufacturers involved in the supply chain?
  • What are the fundamental dynamics (drivers, restraints, opportunities, and challenges) of the market?
  • What and how regulations, schemes, patents, and policies are impacting the growth of the market?
  • How will existing companies adapt to the new change in technology?
  • The market player positioning, top winning strategies by years, company product developments, and launches will be?
  • How has COVID-19 impacted the demand and sales of in the market? Also, the expected BPS drop or rise count of the market and market predicted recovery period.
  • Who are the leading companies operating in the market? Also, who are the prominent startups that disrupt the market in coming years?
  • PUBLISHED ON: MARCH, 2024
  • BASE YEAR: 2023
  • FORECAST PERIOD: 2024-2033
  • STUDY PERIOD: 2019 - 2033
  • COMPANIES COVERED: 15
  • COUNTRIES COVERED: 24
  • NO OF PAGES: 211

Want to Review Complete Market Research Report

 
save 20%
$2450 $1950
 
save 25%
$4450 $3338
 
save 30%
$5850 $4095
 
save 35%
$8150 $5298

Budget constraints? Get in touch with us for special pricing

Request for Special Pricing

Customize this Report

  • Buy specific region or segment sections of this report
  • Buy specific region/country level reports
  • Request for Pricing Analysis, Market Dynamics, Recommendation & Conclusion
  • Companies Profiles based on Target Requirement
  • Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
  • Why Choose Market Statsville Group?
  • CXO’s Perspective
  • Real-Time Market AttractivenessIndex
  • Investment Pockets
  • Market Player Positioning
  • Competitive Heatmap
  • Parent &Peer Market Analysis
  • Primary Survey Analysis & Transcripts
  • Premium insights from industry experts
  • Robust Research Methodology
  • Market Trends & Opportunities
  • Market Growth Dynamics
  • Value/Supply Chain Analysis
  • Pre-&-Post Covid Market Scenario
  • Latest Technological Developments
  • Comprehensive Reports
  • 3-Rounds Quality Checks with Complete Assurance
  • Unlimited Post-Sales Support
  • Regular Report Updates
Didn't Get What you are looking for. Share your requirements here
Request for Customization

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. I Accept